110 related articles for article (PubMed ID: 12834181)
21. Long-term effect of intravenous calcitriol on the treatment of severe hyperparathyroidism, parathyroid gland mass and bone mineral density in haemodialysis patients.
Huraib S; Abu-Aisha H; Abed J; Al Wakeel J; Al Desouki M; Memon N
Am J Nephrol; 1997; 17(2):118-23. PubMed ID: 9096441
[TBL] [Abstract][Full Text] [Related]
22. Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism.
Abdelhadi M; Nordenström J
J Clin Endocrinol Metab; 1998 Nov; 83(11):3845-51. PubMed ID: 9814456
[TBL] [Abstract][Full Text] [Related]
23. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
[TBL] [Abstract][Full Text] [Related]
24. [Effect of salmon calcitonin on bone mineral density and calcium-phosphate metabolism in chronic hemodialysis patients with secondary hyperparathyroidism].
Matuszkiewicz-Rowińska J; Niemczyk S; Przedlacki J; Puka J; Switalski M; Ostrowski K
Pol Arch Med Wewn; 2004 Jul; 112(1):797-803. PubMed ID: 15526839
[TBL] [Abstract][Full Text] [Related]
25. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
26. Effects of parathyroidectomy on bone metabolism in haemodialysis patients with secondary hyperparathyroidism.
Ma L; Zhao S; Li Z
Scand J Clin Lab Invest; 2017 Nov; 77(7):527-534. PubMed ID: 28741963
[TBL] [Abstract][Full Text] [Related]
27. Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients.
El-Shafey EM; Alsahow AE; Alsaran K; Sabry AA; Atia M
Ther Apher Dial; 2011 Dec; 15(6):547-55. PubMed ID: 22107691
[TBL] [Abstract][Full Text] [Related]
28. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
Monier-Faugere MC; Geng Z; Friedler RM; Qi Q; Kubodera N; Slatopolsky E; Malluche HH
Kidney Int; 1999 Mar; 55(3):821-32. PubMed ID: 10027919
[TBL] [Abstract][Full Text] [Related]
29. Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis.
Torregrosa JV; Moreno A; Mas M; Ybarra J; Fuster D
Kidney Int Suppl; 2003 Jun; (85):S88-90. PubMed ID: 12753274
[TBL] [Abstract][Full Text] [Related]
30. Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients: a German-Austrian, single-arm, open-label, prospective, noninterventional, observational study.
Biggar P; Kovarik J; Klauser-Braun R; Graf H; Müller HW; Veres A; Seidinger S; Ketteler M
Nephron Clin Pract; 2014; 126(1):39-50. PubMed ID: 24458019
[TBL] [Abstract][Full Text] [Related]
31. [Clinical study of concerning factors of decreased bone mineral content in hemodialysis patients].
Kohara N
Nihon Jinzo Gakkai Shi; 1991 Jun; 33(6):587-96. PubMed ID: 1920939
[TBL] [Abstract][Full Text] [Related]
32. Management of secondary hyperparathyroidism of dialysis patients.
Akizawa T; Kamimura M; Mizobuchi M; Shiizaki K; Sumikado S; Sakaguchi T; Negi S; Ogata H; Kinugasa E
Nephrology (Carlton); 2003 Oct; 8 Suppl():S53-7. PubMed ID: 15012693
[TBL] [Abstract][Full Text] [Related]
33. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
Khan AA; Bilezikian JP; Kung AW; Ahmed MM; Dubois SJ; Ho AY; Schussheim D; Rubin MR; Shaikh AM; Silverberg SJ; Standish TI; Syed Z; Syed ZA
J Clin Endocrinol Metab; 2004 Jul; 89(7):3319-25. PubMed ID: 15240609
[TBL] [Abstract][Full Text] [Related]
34. Early intervention with intravenous or pulse oral vitamin D therapy is more effective in the treatment of secondary hyperparathyroidism.
Yamada S; Taniguchi M; Tokumoto M; Tsuruya K; Hirakata H; Iida M
Ther Apher Dial; 2010 Aug; 14(4):424-31. PubMed ID: 20649764
[TBL] [Abstract][Full Text] [Related]
35. Changes in bone mineral density after total parathyroidectomy without autotransplantation in the end-stage renal disease patients with secondary hyperparathyroidism.
Fang L; Wu J; Luo J; Wen P; Xiong M; Cao J; Chen X; Yang J
BMC Nephrol; 2018 Jun; 19(1):142. PubMed ID: 29907149
[TBL] [Abstract][Full Text] [Related]
36. An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis.
Chen CL; Chen NC; Hsu CY; Chou KJ; Lee PT; Fang HC; Renn JH
J Clin Endocrinol Metab; 2014 Jul; 99(7):2426-32. PubMed ID: 24670088
[TBL] [Abstract][Full Text] [Related]
37. [Changes in calcium metabolism after parathyroidectomy in primary hyperparathyroidism].
Berczi C; Balogh A; Balázs G; Lukács G
Orv Hetil; 2002 Mar; 143(12):597-600. PubMed ID: 11963396
[TBL] [Abstract][Full Text] [Related]
38. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism.
Lien YH; Silva AL; Whittman D
Nephrol Dial Transplant; 2005 Jun; 20(6):1232-7. PubMed ID: 15840675
[TBL] [Abstract][Full Text] [Related]
39. Effect of intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients.
Liou HH; Chiang SS; Tsai SC; Chang CC; Wu SC; Shieh SD; Huang TP
Zhonghua Yi Xue Za Zhi (Taipei); 1994 Jun; 53(6):319-24. PubMed ID: 8087705
[TBL] [Abstract][Full Text] [Related]
40. A randomised clinical study of alfacalcidol and paricalcitol.
Hansen D
Dan Med J; 2012 Feb; 59(2):B4400. PubMed ID: 22293059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
